Expressions of MAGE-A9 and MAGE-A11 in Breast Cancer and their Expression Mechanism

Archives of Medical Research

Volumn 45, Issue 1, 2014, Pages 44-51

  Hou, Shu yun ^a   Sang, Mei xiang ^a   Geng, Cui zhi ^a   Liu, Wei hua ^a,b   Lü, Wei hua ^a   Xu, Ying ying ^a   Shan, Bao en ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Shijiazhuang Center for Disease Control and Prevention   (China)

Author keywords

5 aza CdR; Breast cancer; MAGE A11; MAGE A9; TSA

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CANCER TESTIS ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROTEIN; PROTEIN MAGE A11; PROTEIN MAGE A9; TRICHOSTATIN A; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER PATIENT; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE SECTION;

5-AZA-CDR; BREAST CANCER; MAGE-A11; MAGE-A9; TSA;

ADULT; ANTIGENS, NEOPLASM; AZACITIDINE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA MODIFICATION METHYLASES; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTORS, ESTROGEN;

EID: 84892524555     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.10.005     Document Type: Article

References (31)

1. Mashino K., Sadanaga N., Tanaka F., et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001, 85:713-720.
2. Zendman A.J., Ruiter D.J., Van Muijen G.N. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003, 194:272-288.
3. Caballero O.L., Chen Y.T. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014-2021.
4. Meek D.W., Marcar L. MAGE-A antigens as targets in tumour therapy. Cancer Lett 2012, 324:126-132.
5. Simpson A.J., Caballero O.L., Jungbluth A., et al. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005, 5:615-625.
6. Chomez P., De Backer O., Bertrand M., et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001, 61:5544-5551.
7. De Smet C., Lurquin C., Lethé B., et al. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol Cell Biol 1999, 19:7327-7335.
8. Adair S.J., Hogan K.T. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother 2009, 58:589-601.
9. Wischnewski F., Pantel K., Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and-A12 in human cancer cells. Mol Cancer Res 2006, 4:339-349.
10. De Plaen E., Arden K., Traversari C., et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics 1994, 40:360-369.
11. Brasseur F., Rimoldi D., Liénard D., et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995, 63:375-380.
12. Otte M., Zafrakas M., Riethdorf L., et al. MAGE-A gene expression pattern in primary breast cancer. Cancer Res 2001, 61:6682-6687.
13. Grau E., Oltra S., Martínez F., et al. MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors. J Cancer Res Clin Oncol 2009, 135:523-531.
14. Bergeron A., Picard V., LaRue H., et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer 2009, 125:1365-1371.
15. Peikert T., Specks U., Farver C., et al. Melanoma antigen A4 is expressed in non-small cell lung cancers and promotes apoptosis. Cancer Res 2006, 66:4693-4700.
16. Kim K.H., Choi J.S., Kim I.J., et al. Promoter hypomethylation and reactivation of MAGE-A1 and MAGE-A3 genes in colorectal cancer cell lines and cancer tissues. World J Gastroenterol 2006, 12:5651-5657.
17. Yan L., Yang X., Davidson N.E. Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia 2001, 6:183-192.
18. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998, 16:413-428.
19. Ross J.S., Fletcher J.A., Linette G.P., et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003, 8:307-325.
20. Yeon C.H., Pegram M.D. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 2005, 23:391-409.
21. Sang M., Lian Y., Zhou X., et al. MAGE-A family: attractive targets for cancer immunotherapy. Vaccine 2011, 29:8496-8500.
22. Schrump D.S., Fischette M.R., Nguyen D.M., et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006, 12:5777-5785.
23. Weiser T.S., Ohnmacht G.A., Guo Z.S., et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg 2001, 71:295-301.
24. Bestor T.H. Gene silencing. Methylation meets acetylation. Nature 1998, 393:311-312.
25. Billard L.M., Magdinier F., Lenoir G.M., et al. MeCP2 and MBD2 expression during normal and pathological growth of the human mammary gland. Oncogene 2002, 21:2704-2712.
26. Picard V., Bergeron A., Larue H., Fradet Y. MAGE-A9 mRNA and protein expression in bladder cancer. Int J Cancer 2007, 120:2170-2177.
27. Donadelli M., Costanzo C., Faggioli L., et al. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog 2003, 38:59-69.
28. Sang M., Wang L., Ding C., et al. Melanoma-associated antigen genes-an update. Cancer Lett 2011, 302:85-90.
29. Gajewski T.F., Fallarino F., Ashikari A., et al. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 2001, 7:895s-901s.
30. Marchand M., Punt C.J., Aamdal S., et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003, 39:70-77.
31. Karanikas V., Lurquin C., Colau D., et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol 2003, 171:4898-4904.